Friday, 22 Jun 2018

You are here

MPO Antibodies Predict Relapses in MPO-ANCA-Associated Vasculitis

A study of MPO-ANCA positive patients followed serially over 2 years shows that reappearance of MPO‐ANCA may predict  relapse in patients with MPO‐ANCA positive AAV and that routine MPO‐ANCA monitoring is warranted. 

This study aimed to establish a potential link between myeloperoxidase (MPO)‐antineutrophil cytoplasmic antibody (ANCA) and relapse in those with ANCA‐associated vasculitis (AAV). 

It is generally known that PR3-ANCA is generally associated with granulomatosis with polyangiitis (GPA), MPO-ANCA is regarded as a marker for microscopic polyangiitis (MPA)/renal-limited disease. While both are diagnostically important, their predictive value is less certain.  

From two Japanese cohort studies (477 patients),.271 were  MPO‐ANCA positive and met enrollment criteria. Of these, 183 had microscopic polyangiitis, 34 GPA, 15 with eosinophilic granulomatosis with polyangiitis, and 39 were unclassifiable.

In the vast majority, (72%) MPO‐ANCA levels decreased to normal levels within 6 months of treatment. 

Reappearance of MPO‐ANCA was seen in 73 (40%) of 181 patients with complete follow‐up data. Reappearance of MPO‐ANCA was more frequent in thos with a relapse (odds ratio = 26.2 [8.2–101], P < 0.0001) after adjusting for confounding factors.

Routine MPO‐ANCA monitoring should be implemented in patients with MPO AAV and this may be a useful biomarker for predicting relapse.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Abatacept Misses in Lupus Nephritis

Dr. Richard Furie, MD, of Northwell Health in New York, presented the findings ofa large phase III trial of abatacept (Orencia) in lupus nephritis showing the agent failed to achieve a complete renal response.

Data presented at EULAR 2018 showed that at one year, a total of 35.1% of patients receiving abatacept achieved complete renal response, as did 33.5% of those randomized to placebo (P=0.73). 

The Stress - Autoimmune Disease Connection

"Can stresss be the cause of my autoimmune disease?" is an often launched question met with shrugs of uncertainty or strongly held beliefs rooted in bias moreso than fact.

Swedish investigators have analyzed a large registry cohort and shown that exposure to stress-related disorders yields a significantly increased risk of autoimmune disease. They analyzed 106,464 patients with stress-related disorders, with 126,652 full siblings, and over a million non-stressed matched controls to assess a future risk of autoimmune disease.

The Microbiome and Lupus Connection Reviewed

In the current issue of the New England Journal of Medicine, Drs. James Rosenbaum and Gregg Silverstein review the pathogenesis of systemic lupus erythematosus (SLE) from the viewpoint of a dysbiolsis.

The complexity of the trillions of organisms that constitute our microbiome underscores its multiplicity of functions, including nutrient, metabolic and immune shaping functions.

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc.

Low Disease Activity in Lupus Limits Damage

Patients with systemic lupus erythematosus (SLE) who were assessed as being in a low disease activity state during more than half of clinical visits had a decrease in organ damage events of approximately 50%, a retrospective study found.